Cryosite (ASX:CTE) Tariff Resilience Score: 0/10 (As of Jul. 02, 2026)


ASX:CTE Cryosite Ltd ASX:CTE
47 GF Score
Price A$1.25
GF Value A$0.95
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cryosite Tariff Resilience Score?

Cryosite has the Tariff Resilience Score of 0, which implies that the company might have .

Cryosite has

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Cryosite might have .

Cryosite  (ASX:CTE) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Cryosite Tariff Resilience Score Related Terms

ASX:CTE
47GF Score
Cryosite Ltd ASX:CTE
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cryosite (ASX:CTE) Overvalued in 2026?

Based on GuruFocus' analysis, Cryosite stock appears to be overvalued. The current stock price of A$1.25 is trading 31.6% above its estimated GF Value™ of A$0.95. GuruFocus considers Cryosite to be Significantly Overvalued.

Key valuation signals for ASX:CTE:

  • Tariff Resilience Score: 0
  • GF Value™: A$0.95 vs. price of A$1.25 (31.6% above fair value)
  • GF Score™: 47/100 with 3 warning signs

No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cryosite Business Description

Address 13a Ferndell Street, South Granville, Sydney, NSW, AUS, 2142
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
47GF Score

Get the complete analysis for ASX:CTE

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$1.25
Price
A$0.95
GF Value